Download PDF
J Neurol Surg A Cent Eur Neurosurg 2022; 83(06): 548-554
DOI: 10.1055/s-0041-1739501
Original Article

Preoperative Thrombocytosis is Not Associated with Overall Survival in 309 Glioblastoma Patients

Sascha Marx
1   Department of Neurosurgery, University Medicine Greifswald, Greiswald, Germany
,
Robert Altmann
1   Department of Neurosurgery, University Medicine Greifswald, Greiswald, Germany
,
Marcel Baschin
2   Department of Transfusion Medicine, University Medicine Greifswald, Greifswald, Germany
,
Heiko Paland
3   Department of Pharmacology, University Medicine Greifswald, Greifswald, Germany
,
Bernhard Rauch
3   Department of Pharmacology, University Medicine Greifswald, Greifswald, Germany
,
Thomas Kohlmann
4   Institute for Community Medicine, University Medicine Greifswald, Greifswald, Germany
,
Henry W. S. Schroeder
1   Department of Neurosurgery, University Medicine Greifswald, Greiswald, Germany
› Author Affiliations
› Further Information
Also available at
    Permissions and Reprints

Abstract

Background In recent years, a correlation of thrombocytosis and a worse prognosis was shown for many solid cancers, including glioblastoma multiforme (GBM).

Methods A retrospective review was performed for all patients with a histologically proven and first-diagnosed GBM between 2005 and 2015 in our department. Clinical and paraclinical parameters were acquired from patient documentation and structured for subsequent data analysis. The association of potential risk factors with overall survival was assessed using the Kaplan–Meier survival analysis and Cox regression.

Results The present study includes 309 patients first diagnosed with primary GBM. Our analyses validate well-known risk factors of a decreased overall survival such as higher patient age, a larger preoperative tumor volume, Karnofsky performance status, extent of resection, tumor localization, and adjuvant treatment. However, no correlation was observed between a preoperative thrombocytosis, the mean platelet volume, leucocyte count, activated partial thromboplastin time (apTT), fibrinogen level, and acetylsalicylic acid 100 co-medication. Patients with preoperative hemoglobin below 7.5 mmol/L had decreased overall survival.

Conclusion The present study, enrolling the largest numbers of patients assessing this topic to date, did not find any association between a preoperative thrombocytosis and overall survival in 309 patients with GBM.

Keywords

platelet count - overall survival - glioblastoma - aspirin - hemoglobin


Publication History

Received: 01 December 2020

Accepted: 14 May 2021

Article published online:
12 December 2021

© 2021. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 Buller HR, van Doormaal FF, van Sluis GL, Kamphuisen PW. Cancer and thrombosis: from molecular mechanisms to clinical presentations. J Thromb Haemost 2007; 5 (Suppl. 01) 246-254
    CrossrefPubMedGoogle Scholar
  • 2 Buergy D, Wenz F, Groden C, Brockmann MA. Tumor-platelet interaction in solid tumors. Int J Cancer 2012; 130 (12) 2747-2760
    CrossrefPubMedGoogle Scholar
  • 3 Stupp R, Mason WP, van den Bent MJ. et al; European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups, National Cancer Institute of Canada Clinical Trials Group. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005; 352 (10) 987-996
    CrossrefPubMedGoogle Scholar
  • 4 Brockmann MA, Giese A, Mueller K. et al. Preoperative thrombocytosis predicts poor survival in patients with glioblastoma. Neuro-oncol 2007; 9 (03) 335-342
    CrossrefPubMedGoogle Scholar
  • 5 Lopes M, Carvalho B, Vaz R, Linhares P. Influence of neutrophil-lymphocyte ratio in prognosis of glioblastoma multiforme. J Neurooncol 2018; 136 (01) 173-180
    CrossrefPubMedGoogle Scholar
  • 6 Cho SY, Yang JJ, You E. et al. Mean platelet volume/platelet count ratio in hepatocellular carcinoma. Platelets 2013; 24 (05) 375-377
    CrossrefPubMedGoogle Scholar
  • 7 Inagaki N, Kibata K, Tamaki T, Shimizu T, Nomura S. Prognostic impact of the mean platelet volume/platelet count ratio in terms of survival in advanced non-small cell lung cancer. Lung Cancer 2014; 83 (01) 97-101
    CrossrefPubMedGoogle Scholar
  • 8 Osada J, Rusak M, Kamocki Z, Dabrowska MI, Kedra B. Platelet activation in patients with advanced gastric cancer. Neoplasma 2010; 57 (02) 145-150
    CrossrefPubMedGoogle Scholar
  • 9 Wang X, Cui MM, Xu Y. et al. Decreased mean platelet volume predicts poor prognosis in invasive bladder cancer. Oncotarget 2017; 8 (40) 68115-68122
    CrossrefPubMedGoogle Scholar
  • 10 Cappellini MD, Motta I. Anemia in clinical practice-definition and classification: does hemoglobin change with aging?. Semin Hematol 2015; 52 (04) 261-269
    CrossrefPubMedGoogle Scholar
  • 11 Lombardi G, Rumiato E, Bertorelle R. et al. Clinical and genetic factors associated with severe hematological toxicity in glioblastoma patients during radiation plus temozolomide treatment: a prospective study. Am J Clin Oncol 2015; 38 (05) 514-519
    CrossrefPubMedGoogle Scholar
  • 12 Zhang F, Guo X, Xing B, Yang Y, Xu Z. Hepatic and renal functions and blood cell counts in brain tumor patients during the perioperative period. J Clin Neurosci 2019; 69: 190-197
    CrossrefPubMedGoogle Scholar
  • 13 Wick W, Weller M, van den Bent M. et al. MGMT testing: the challenges for biomarker-based glioma treatment. Nat Rev Neurol 2014; 10 (07) 372-385
    CrossrefPubMedGoogle Scholar
  • 14 Goubran HA, Burnouf T, Radosevic M, El-Ekiaby M. The platelet-cancer loop. Eur J Intern Med 2013; 24 (05) 393-400
    CrossrefPubMedGoogle Scholar
  • 15 Jain S, Harris J, Ware J. Platelets: linking hemostasis and cancer. Arterioscler Thromb Vasc Biol 2010; 30 (12) 2362-2367
    CrossrefPubMedGoogle Scholar
  • 16 Williams M, Liu ZW, Woolf D. et al. Change in platelet levels during radiotherapy with concurrent and adjuvant temozolomide for the treatment of glioblastoma: a novel prognostic factor for survival. J Cancer Res Clin Oncol 2012; 138 (10) 1683-1688
    CrossrefPubMedGoogle Scholar
  • 17 Marx S, Splittstöhser M, Kinnen F. et al. Platelet activation parameters and platelet-leucocyte-conjugate formation in glioblastoma multiforme patients. Oncotarget 2018; 9 (40) 25860-25876
    CrossrefPubMedGoogle Scholar
  • 18 Bloch O, Crane CA, Kaur R, Safaee M, Rutkowski MJ, Parsa AT. Gliomas promote immunosuppression through induction of B7-H1 expression in tumor-associated macrophages. Clin Cancer Res 2013; 19 (12) 3165-3175
    CrossrefPubMedGoogle Scholar
  • 19 Markovic DS, Vinnakota K, Chirasani S. et al. Gliomas induce and exploit microglial MT1-MMP expression for tumor expansion. Proc Natl Acad Sci U S A 2009; 106 (30) 12530-12535
    CrossrefPubMedGoogle Scholar
  • 20 Ye XZ, Xu SL, Xin YH. et al. Tumor-associated microglia/macrophages enhance the invasion of glioma stem-like cells via TGF-β1 signaling pathway. J Immunol 2012; 189 (01) 444-453
    CrossrefPubMedGoogle Scholar
  • 21 Jimsheleishvili S, Alshareef AT, Papadimitriou K. et al. Extracranial glioblastoma in transplant recipients. J Cancer Res Clin Oncol 2014; 140 (05) 801-807
    CrossrefPubMedGoogle Scholar
  • 22 Müller C, Holtschmidt J, Auer M. et al. Hematogenous dissemination of glioblastoma multiforme. Sci Transl Med 2014; 6 (247) 247ra101
    CrossrefPubMedGoogle Scholar
  • 23 Nilsson RJ, Balaj L, Hulleman E. et al. Blood platelets contain tumor-derived RNA biomarkers. Blood 2011; 118 (13) 3680-3683
    CrossrefPubMedGoogle Scholar
  • 24 Meikle CK, Kelly CA, Garg P, Wuescher LM, Ali RA, Worth RG. Cancer and thrombosis: the platelet perspective. Front Cell Dev Biol 2017; 4: 147
    CrossrefPubMedGoogle Scholar
  • 25 Placke T, Kopp HG, Salih HR. Modulation of natural killer cell anti-tumor reactivity by platelets. J Innate Immun 2011; 3 (04) 374-382
    CrossrefPubMedGoogle Scholar
  • 26 Han S, Liu Y, Li Q, Li Z, Hou H, Wu A. Pre-treatment neutrophil-to-lymphocyte ratio is associated with neutrophil and T-cell infiltration and predicts clinical outcome in patients with glioblastoma. BMC Cancer 2015; 15: 617
    CrossrefPubMedGoogle Scholar
  • 27 Subeikshanan V, Dutt A, Basu D, Tejus MN, Maurya VP, Madhugiri VS. A prospective comparative clinical study of peripheral blood counts and indices in patients with primary brain tumors. J Postgrad Med 2016; 62 (02) 86-90
    CrossrefPubMedGoogle Scholar
  • 28 Daugherty SE, Pfeiffer RM, Sigurdson AJ. et al. Nonsteroidal antiinflammatory drugs and bladder cancer: a pooled analysis. Am J Epidemiol 2011; 173 (07) 721-730
    CrossrefPubMedGoogle Scholar
  • 29 Brockmann MA, Bender B, Plaxina E. et al. Differential effects of tumor-platelet interaction in vitro and in vivo in glioblastoma. J Neurooncol 2011; 105 (01) 45-56
    CrossrefPubMedGoogle Scholar